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Abstract
Sickle cell disease affects more than 100,000 individuals in the United States, among whom 
disease severity varies considerably. One factor that influences disease severity is the sickle cell 
disease genotype. For this reason, clinical prevention and treatment guidelines tend to differentiate 
between genotypes. However, previous research suggests caution when using a claimsbased 
determination of sickle cell disease genotype in healthcare quality studies.
The objective of this study was to describe the extent of miscoding for the major sickle cell disease 
genotypes in hospital discharge data. Individuals with sickle cell disease were identified through 
newborn screening results or hemoglobinopathy specialty care centers, along with their sickle cell 
disease genotypes. These genotypes were compared to the diagnosis codes listed in hospital 
discharge data to assess the accuracy of the hospital codes in determining sickle cell disease 
genotype. Eighty-three percent (sickle cell anemia), 23% (Hemoglobin SC), and 31% 
(Hemoglobin Sβ+ thalassemia) of hospitalizations contained a diagnosis code that correctly 
reflected the individual's true sickle cell disease genotype. The accuracy of the sickle cell disease 
genotype coding was indeterminate in 11% (sickle cell anemia), 12% (Hemoglobin SC), and 7% 
(Hemoglobin Sβ+ thalassemia) and incorrect in 3% (sickle cell anemia), 61% (Hemoglobin SC), 
and 52% (Hemoglobin Sβ+ thalassemia) of the hospitalizations. The use of ICD-9-CM codes from 
hospital discharge data for determining specific sickle cell disease genotypes is problematic. 
Research based solely on these or other types of administrative data could lead to incorrect 
understanding of the disease.
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Background
Sickle cell disease (SCD) is characterized by chronic hemolytic anemia and a wide variety 
of acute and chronic complications caused by intermittent episodes of vaso-occlusion, 
vascular injury, and organ damage. SCD affects more than 100,000 individuals in the United 
States1 and with recent advances in care, individuals with SCD are living longer2. Even so, 
disease severity varies considerably among individuals. While some exhibit severe 
complications and die before reaching middle age, others are far less symptomatic3.
One factor that influences disease severity is the SCD genotype. In the United States, most 
individuals with SCD have homozygous hemoglobin (Hb) SS disease (Hb SS), and the 
remainder have a compound heterozygous form of SCD caused by co-inheritance of Hb S 
with a different beta globin mutation such as Hb C or a variety of β thalassemia mutations4. 
The Hb Sβ thalassemias are divided into two groups depending on the severity of the β 
thalassemia mutation; mutations that result in absent production of β globin are termed Hb 
Sβ0 thalassemia while those that result in reduced, but not absent, production of β globin are 
termed Hb Sβ+ thalassemia. Individuals with Hb SS or Hb Sβ0 thalassemia are classified as 
having sickle cell anemia (SCA) because their hematological phenotype is characterized by 
a more severe chronic hemolytic anemia than those with Hb SC or Hb Sβ+ thalassemia, who 
have less hemolysis and less severe or no anemia. In the United States, Hb SC is the most 
prevalent of the compound heterozygous SCD genotypes, followed by Hb Sβ+ thalassemia 
and then Hb Sβ0 thalassemia. A recent population-based surveillance study from six states 
found that 61.4% of individuals with SCD had SCA, 28.3% had Hb SC, 8.5% had Hb Sβ+ 
thalassemia, and 1.8% had another compound heterozygous form of SCD5.
It is sometimes difficult to distinguish between the two SCA genotypes because the co-
inheritance of α thalassemia in persons with Hb SS results in significant overlap of complete 
blood count and hemoglobin electrophoresis results in persons with Hb Sβ0 thalassemia. 
Therefore, the genotypes cannot be reliably differentiated without DNA analysis. However, 
the distinction between SCA and Hb SC/Hb Sβ+ thalassemia is important because the risk 
for some of the more severe complications of SCD, such as stroke, is much higher in SCA 
than in Hb SC/Hb Sβ+ thalassemia, especially during childhood6. For this reason, clinical 
prevention and treatment guidelines tend to differentiate between genotypes in their practice 
recommendations based on evidence of clinical effectiveness and differing risk- benefit 
trade-offs. For example, annual transcranial Doppler screening for prevention of stroke in 
childhood is recommended for children with SCA but not for those with Hb SC or Hb Sβ+ 
thalassemia. Similarly, indications for use of hydroxyurea are much broader and more 
inclusive for SCA compared to Hb SC or Hb Sβ+ thalassemia7.
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
codes have been commonly used by public health officials and health services researchers to 
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identify individuals with SCD to evaluate complications, adherence to treatment guidelines, 
and the quality of care received. Because researchers have questioned the accuracy of SCD 
genotypes based on ICD-9-CM codes8,9, studies usually identify patients based on any SCD 
code (282.41-42, 282.6, 282.60-64, 282.68-69) in any position, primary, secondary or 
other10-13. A few of these studies have reported results by genotype, including reports 
detailing rehospitalizations14, influenza15, stroke16, and surgical outcomes for individuals 
with SCD17. Furthermore, some studies have been restricted to individuals with Hb SS 
codes only18-20 and others were limited to only individuals with ICD-9-CM codes for SCD 
crisis21-24. In only one instance has the accuracy of coding by SCD genotype been 
reported25. In that report, findings from an analysis of emergency department visits at a 
children's hospital found that ICD-9-CM codes for Hb SS were 87% accurate, but the Hb SS 
codes were very often used for ED visits of patients with other genotypes. Therefore, the 
authors suggested caution when using a claims-based determination of SCD genotype in 
healthcare quality studies.
Georgia and California have a unique set of SCD surveillance data collected through the 
Registry and Surveillance System for Hemoglobinopathies (RuSH)5. These population-
based data can be used to test the accuracy of hospital discharge data for identifying SCD 
genotypes and, in turn, their utility in evaluating adherence to practice recommendations that 
differ by genotype. This is possible by comparing ICD-9-CM codes from the hospital 
discharge data to laboratory-based information collected from clinical sites and state 
newborn screening programs within the RuSH surveillance datasets. The purpose of this 
study was to use the hospital discharge records of a population-based sample to (1) describe 
the extent of miscoding for the major SCD genotypes and estimate the accuracy of ICD-9-
CM codes and (2) report the positive predictive value of using Hb SS ICD-9-CM codes only 
(282.61 and 282.62) to identify individuals with SCA.
Methods
The methods that California and Georgia used to collect and link population-based SCD 
surveillance data for 2004 to 2008 from a variety of sources were previously described5. The 
analyses presented here include individuals with SCD who were reported by newborn 
screening and/or one of the participating hemoglobinopathy specialty treatment centers 
(Georgia: Georgia Comprehensive Sickle Cell Center at Grady Memorial, Georgia Health 
Sciences University, and all three campuses of Children's Healthcare of Atlanta; California: 
University of California (UC) San Francisco Benioff Children's Hospital Oakland and San 
Francisco, Children's Hospital Los Angeles, UC Irvine Medical Center, Rady UC San 
Diego, UC Davis Medical Center) with a laboratory-confirmed diagnosis based on results of 
clinical laboratory evaluation that included quantitative hemoglobin identification by 
hemoglobin electrophoresis, high-performance liquid chromatography or DNA analysis. 
These individuals were then linked to inpatient files from each state's hospital discharge data 
(all records from 2004 to 2008) using multiple patient identifiers. This study only included 
individuals who had at least one hospitalization reported during the five year period.
The hospital discharge data from Georgia included a maximum of ten diagnosis codes per 
admission; in the California data there were up to 25 diagnosis codes per admission. All of 
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the diagnosis codes were scanned for the presence of an SCD ICD-9-CM code. These SCD 
codes were then compared to the known SCD genotype for the individual, and a 
determination of “correct,” “indeterminate,” “incorrect,” or “no code” was made, based on 
whether or not the diagnosis code and the known SCD genotype were considered to be a 
correct match (Figure 1). These categorizations were defined from the perspective of the 
known SCD genotype. That is, for a hospitalization of an individual with SCA, the “sickle-
cell thalassemia with/without crisis” (282.41, 282.42) ICD-9-CM codes would be “correct” 
if the individual had Hb Sβ0 thalassemia, but incorrect if the individual had Hb SS, so the 
comparison was termed “indeterminate.” On the other hand, a hospitalization of an 
individual with Hb Sβ+ thalassemia would be termed “correct,” if the same codes were 
listed.
Hospital admissions for individuals with SCD genotypes other than Hb SS/Hb Sβ0 
thalassemia, Hb SC, or Hb Sβ+ thalassemia are provided in Table 1, but were excluded from 
further analyses (n=78 California; n=68 Georgia). Admissions that included more than one 
SCD related ICD-9-CM diagnosis code were also removed (n=18 California, n=119 
Georgia). The data analysis for this study was generated using SAS® version 9.3 (SAS 
Institute, 2010).
Results
The RuSH surveillance project identified a total of 6,264 individuals with a known SCD 
genotype in California and Georgia; 1,976 in California and 4,288 in Georgia. Of these, 
3,961 (63.2%) accounted for a total of 27,439 hospitalizations during 2004 through 2008 
(Table 1); 43.2% were for pediatric patients aged 18 years or younger at the time of 
admission, and 46.8% were male patients. Individuals with SCA accounted for 72.5% of the 
patients with a known genotype and 79.9% of the hospital discharges; Hb SC accounted for 
21.4% of patients and 15.3% of discharges; Hb Sβ+ thalassemia accounted for 5.5% of 
patients and 4.2% of discharges.
ICD-9-CM coding correctly identified SCA genotypes in 82.9% of hospitalizations (78.9% 
in CA, 84.5% in GA), while the coding was incorrect in 3.4% (4.5% in CA, 2.9% in GA) 
and indeterminate in 11.4% (15.4% in CA, 9.7% in GA). However, coding for Hb SC was 
correct in only 22.8% (24.4% in CA, 22.1% in GA) of hospitalizations, incorrect in 60.9% 
(64.5% in CA, 59.3% in GA) and indeterminate in 11.5% (8.0% CA, 13.1% GA). 
Individuals with Hb Sβ+ thalassemia were correctly coded in only 30.5% of hospitalizations 
overall; substantially higher in CA (56.2%) than in GA (22.4%). Coding for Hb Sβ+ 
thalassemia was incorrect in 52.2% (26.3% in CA, 60.3% in GA), and indeterminate in 7.0% 
(6.6% in CA, 7.2% in GA) (Figure 2). Two percent of hospitalizations for individuals with 
SCD in California and 4% in Georgia did not contain an SCD ICD-9-CM diagnosis code. 
The lack of any SCD diagnosis code was higher for Hb Sβ+ thalassemia (10.3%) compared 
with Hb SC (4.7%) and SCA (2.3%).
In our cohort of hospitalizations for individuals with SCD from both California and Georgia, 
using Hb SS ICD-9-CM codes only (282.61, 282.62) versus any SCD code to identify a 
pediatric patient with SCA improved the positive predictive value (PPV) from 84% 
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(9,850/11,740) to 93% (7,750/8,306); however, in the adult population the PPV only slightly 
improved from 79% (12,229/15,435) to 81% (10,352/12,752) (Table 2).
Discussion
One of the most important distinctions to make, when treating patients with SCD or 
evaluating their health and healthcare utilization patterns, is between patients with SCA 
genotypes and patients with other forms of SCD, because patients with SCA are at a higher 
risk for many disease-related complications and hospitalization14,26. However, the use of 
ICD-9-CM codes for determining specific SCD genotypes is problematic for multiple 
reasons. First, although it is sometimes difficult to distinguish Hb SS from Hb Sβ0 
thalassemia based on results of hemoglobin electrophoresis or other non DNA tests, there is 
no single ICD-9-CM code for SCA, rather there are separate codes for “hemoglobin-SS 
disease with/without crisis” (282.61, 282.62) and “sickle-cell thalassemia with/without 
crisis” (282.41, 282.42). Furthermore, the latter ICD-9-CM codes do not differentiate 
between Hb Sβ0 thalassemia and Hb Sβ+ thalassemia, the former genotype causing SCA, 
while the latter does not. The difficulty in distinguishing between SCA genotypes, even with 
the presence of laboratory-based results, is the reason that the SCD surveillance data 
collected by Georgia and California, and used for the analyses presented here, utilized an 
SCA classification, rather than separate Hb SS and Hb Sβ0 thalassemia genotypes. 
Moreover, the limitations of the ICD-9-CM codes for determining SCD genotypes were the 
reason that the SCD surveillance data collected on individuals without a newborn screening 
report or diagnosis from a hemoglobinopathy specialty treatment center did not contain 
genotype information and were, therefore, excluded from this analysis.
In addition to the inherent limitations of the SCD ICD-9-CM codes themselves, our study 
indicates that there is also misuse of these codes, as has been previously reported25. That 
study from a single pediatric emergency department noted that the accuracy of correctly 
identifying individuals with Hb SS was 87%, with sensitivity, specificity, and PPV of 87%, 
79%, and 87% respectively. Our study showed the accuracy of identifying individuals with 
SCA in hospital discharge data was similar. However the accuracy of ICD-9-CM codes to 
identify other SCD genotypes was poor, especially for individuals with Hb SC; over 75% of 
their hospitalizations contained an ICD-9-CM code that did not match their true SCD 
genotype. For Hb Sβ+ thalassemia, accuracy was also low (69%). This miscoding may be, in 
part, because some healthcare providers and coders do not appreciate the differences among 
SCD genotypes, leading to the use of Hb SS codes for non-Hb SS genotypes. While these 
analyses were based on ICD-9-CM codes, it is important to recognize that the ICD-10-CM 
codes for SCD that are now being used have similar limitations.
The lack of SCA ICD-9-CM codes, ambiguous codes for Hb Sβ0 thalassemia vs Hb Sβ+ 
thalassemia, and the high rates of mismatch between true SCD genotype and the SCD 
ICD-9-CM codes in hospital discharge data may lead to the erroneous interpretation of such 
data and mistaken conclusions. Using hospital discharge data to analyze hospital admission 
and/or readmission rates, the rate of a particular surgical procedure, or adherence to 
recommended therapy by genotype could incorrectly classify up to 15% of individuals with 
SCA, three-fourths of those with Hb SC, and over two-thirds of those with Hb Sβ+ 
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thalassemia. Errors such as these could lead to incorrect understanding of the disease and 
adherence to recommended management and treatment. Our results suggest that caution 
should be exercised when interpreting research that relies solely on hospital discharge data 
to identify and determine the genotype of individuals with SCD.
The results presented here further suggest that using only Hb SS ICD-9-CM codes to 
identify individuals with SCA improves the genotypic accuracy of the resulting sample for 
pediatric patients when compared to using all SCD ICD-9-CM codes, but does little to 
improve identification of adults with SCA. These results are due, in part, to the high rates of 
miscoding for non-SCA genotypes, as well as the higher rates of hospitalization in 
individuals with SCA (80% of the SCD hospitalizations in this analysis, but only 73% of the 
patients with a hospitalization and 64% of all identified individuals with SCD, regardless of 
hospitalization).
A fundamental strength of this study is the identification of cohort members through 
population-based surveillance, rather than identification solely in administrative data or a 
SCD specialty clinic(s). While the use of administrative data alone requires fewer resources, 
it is often incomplete and may suffer from suboptimal quality. Data from SCD specialty 
clinics have higher quality and more complete reporting, but contain a limited number of 
cases and may not represent a population-based sample of all patients.
This analysis also has limitations. It has a narrow focus on hospital discharge data, thus 
excluding the 37.7% of patients with known SCD genotypes who were not hospitalized 
during the five year period. Results from other commonly used administrative datasets, such 
as Medicaid or emergency department claims data, may show levels of congruence between 
true SCD genotype and ICD-9-CM genotype that vary from the results presented here. 
Furthermore, this study did not include individuals with SCD for whom a laboratory-
confirmed genotype was not available. That is, the individuals who were neither born in 
California or Georgia during the years of active newborn screening nor receiving care from 
one of the participating clinics. Finally, there were a large number of hospitalizations during 
this five-year study period that contained an SCD ICD-9-CM code, but were not linked to 
our cohort.
These findings underscore the need for surveillance systems that can accurately identify 
individuals living with SCD along with their correct genotype, track their health care 
utilization, and monitor their quality of care by measuring adherence to practice guidelines 
in ways that have the potential to reduce SCD associated morbidity and mortality and 
improve care. Until a national registry or other data collection system is available for SCD in 
the US, researchers will be limited by the accuracy of ICD-9-CM or, since late 2015, 
ICD-10-CM codes for determining SCD genotype. Therefore, caution must be used when 
interpreting results and applying findings to the development of practice guidelines or 
recommendations for clinical care.
Snyder et al. Page 6
J Rare Dis Res Treat. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Note
This project was reviewed by CDC and was determined to be a non-research, public health 
practice activity. Both the California Committee for Protection of Human Subjects and the 
Georgia Public Health Department Institutional Review Board declared the project exempt 
from review as a public health surveillance effort; specialty hemoglobinopathy treatment 
center institutional review boards similarly exempted the project from review. State data 
requests were reviewed by the appropriate agency, assuring data privacy safeguards were in 
place. The findings and conclusions in this report are those of the authors and do not 
necessarily represent the official position of the Centers for Disease Control and Prevention.
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Figure 1. 
Comparison of known sickle cell disease (SCD) genotype and SCD ICD-9-CM hospital 
discharge code, California and Georgia, 2004-2008. Correct = dots; indeterminate = 
horizontal lines; incorrect = crosshatch
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Figure 2. 
a. Accuracy of ICD-9-CM hospital discharge codes for determining sickle cell disease 
genotype, California, 2004-2008.
b. Accuracy of ICD-9-CM hospital discharge codes for determining sickle cell disease 
genotype, Georgia, 2004-2008.
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Table 2
Positive predictive value of using Hemoglobin SS ICD-9-CM hospital discharge codes (282.61 or 282.62) to 
identify individuals with sickle cell anemia, California and Georgia, 2004-2008
True SCA genotype
Age Group Hb SS code (282.61 or 282.62) Yes No Total
0-18y Yes 7750 556 8306
No 2100 1334 3434
Total 9850 1890 11740
19+y Yes 10352 2400 12752
No 1877 806 2683
Total 12229 3206 15435
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